REMS, or risk evaluation and mitigation strategies, aimed to try and help reduce the level of misuse and abuse of these types of drugs.

There are many drugs in the market that contain this particular painkiller, including fentanyl, OxyContin, as well as others.

The high level of abuse and misuse of these drugs can lead to such things as severe overdose, which has the potential of causing death.

Studies have shown that among all drugs, opioid abuse has caused more deaths than other well-known dangerous drugs such as heroin as well as cocaine.

The advisory panel voted down REMS due to the fact that they did not feel it would be able to help with the misuse and abuse of this type of drug.

The feeling was that this would not be able to do much in regards to helping with the death rate.

Helping with this type of prevention, which included doctor training, may not be the key after all to fighting off opioid abuse.

This landmark decision came down this week as Oakland approved a plan to regulate and allow for the development of large marijuana growers who could help with the demand for more supply within the city and abroad.

The city council in Oakland has voted in favor of giving licenses to 4 very large marijuana production plants or factories if you will.

Within these plants, these companies will be able to grow, package, and send out the marijuana.

Oakland has made history here as they are the first city to allow for this type of mass production of pot.

These marijuana factories would be heavily regulated and will be subjected to taxes, etc. The key here though is that there really is no limit to how big they get.

Those in favor of the plan believe that it could help Oakland’s economy immensely.

This comes as California voters are set to vote on the legalization of recreational marijuana this fall.

The FDA has been going back and forth in regards to whether or not this generic drug would be approved.

The fact of the matter though is that they have given it full approval, and this is likely going to open the doors for similar generics.

The generic form of Lovenox has the same base as the real thing, made from heparin, and has the same positive effect on patients.

The generic drug was developed by the generic division of Novartis, Sandoz.

The technology the generic was created from was developed by a company based in Cambridge, MA.

This technology, from Momenta Pharmaceuticals, is likely going to lead to the cloning of other complex drugs that have very particular mixtures.

We will have to wait and see in regards to just how many more drugs will get approval, but this could certainly open the flood gates up.

New Mexico allows for medical marijuana to be used as a form of treatment, but the issue here is that it is difficult to actually follow all of the guidelines and restrictions put in place to make it work.

The main marijuana growers in the state of New Mexico are unable as of right now to be able to grow enough marijuana to meet the demand of all of the patients who need the pot for medical purposes.

Suppliers argue that there are triple the number of patients who need medical marijuana when compared to the actual supply of pot.

The state of New Mexico has been working to try and get more suppliers set up who meet their guidelines.

The issue is that even once the suppliers are approved it will take a long time for them to have medical marijuana ready.

A new study has shown that the device has more than a 50% chance of extending the lives of patients with heart problems by at least 2-years.

The new study stated that over 50% of patients with end-stage congestive heart failure who received this device were able to live for 2-years longer.

The 69-year-old former Vice President Dick Cheney received a heart pump a week ago in Virginia, known as a ventricular assist device.

Dick Cheney made it clear that he wanted to take advantage of the new medical technology available, as the device basically controls the main pumping of the heart.

This could extend the lives of patients who are nearing the end of their road in the battle against congestive heart failure.

The only sad fact to this is that after the 2-years go by, the chance of survival even with the pump is only 8%.

The bottom line from this though is that many patients with congestive heart failure could use these pumps to extend their lives significantly.

Avastin has been much-anticipated and seen by many as a drug that could really help in the fight against breast cancer.

Early drug trials carried out on the drug revealed that it was actually able to shrink the growth of breast cancer tumors in patients with the disease.

This led the FDA to accelerate the approval process of the breast cancer drug, but it appears that the fast-track approach has back-fired.

The new drug trials set out to see whether or not the breast cancer drug was actually able to extend the lifespan of patients with breast cancer, on top of reducing tumor growth.

The study compared breast cancer patients who received the drug with chemotherapy, and a second group just recceiving chemotherapy.

There was no difference in the survival rate of those who received Avastin when compared to those who did not.

What this coul dmean is that the FDA could decide to pull the drug from the market.

This would harm Roche a great deal as the drug had sales of $6 billion last year alone.

The FDA has yet to make a decision on the drug but will hold meetings this week to see what to do in regards to it.

The warning signs have come over the past months as studies have linked the drug to potential health risks, including an increased risk of heart attack and cardiovascular issues.

A medical advisory panel to the FDA recommended this week that the diabetes drug be pulled from shelves, or at least more vigorously regulated in terms of who uses it.

The FDA did not listen to the advice of the advisory panel though, as they have ruled that the drug maker can continue to sell the product.

The FDA did state though that GlaxoSmithKline was wrong in that they did not report the negative side effect of potential increased risk of heart failure while on the drug.

A new warning label has been ordered by the FDA to be placed on the drug that will highlight the now known to be more severe side effects.

The vote was not quite unanimous to keep Avandia on store shelves, but it was certainly a majority as the vote came in at 20-12 to allow it to continue to be sold.

The FDA typically does follow the advice of medical advisory panels, but in this particular case they saw it best to go against the recommendations.

The report is the result of a global study that was carried out by UNAIDS, and focused on infection rates of HIV in some of the hardest hit countries in the world.

The research was done from 2000 to 2005 and the results are actually very promising when you think about future HIV rates in these countries.

What researchers found was that in many of the most affected countries in the world, HIV infection rates have dropped a great deal among young adults between the ages of 15 to 24.

Countries seeing relief include some of those who are known for HIV infection rates, such as Kenya, as well as Ethiopia.

Overall, HIV infection rates dropped by about 25% among young adults.

Much of this is likely due to better preventive measures, higher levels of awareness, etc.

This is great news when you think about the potential that this could lead to far fewer cases of HIV and AIDS in the years to come.

The U.S. Justice Department charged 94 people in total this week in connection with this absolutely massive fraud operation.

The operation spanned 5 different states in the U.S., with all of them reportedly being in connection to this system that led to over $251 million in false claims to Medicare.

These people charged are not everyday citizens either, they include the owners of major health care businesses, doctors, and many others.

There is a great deal of cohesiveness to these fraud schemes with money coming in and going out to anyone who would help them carry out their scheme.

There were roughly 40 arrests made by the end of the day on Friday.

This is a scary thing considering how much Medicare and the health care industry in general make up the U.S. gross-domestic product (GDP). Health care is our biggest industry and costs our government an incredible amount of money, and to think that it could be taken advantage of in this way is wrong on so many levels.

With so many Americans relying on Medicare, it appears that the system is now much safer thanks to the work of the U.S. federal agents who are bringing those responsible for the fraud to justice.

The FDA released a report on Tuesday which focused on the new weight-loss drug following the results of a study.

What the results revealed were pretty startling, as the FDA stated that those who were on the drug were able to lose weight.

Roughly 10% of those who were on the weight loss drug for the study were said to have significant weight loss.

Previous studies on the drug have also shown that weight loss is certainly possible.

The biggest hurdle surrounding this drug now though is the fact that side-effects do exist, and that has the FDA worries.

The latest study has revealed that those on the highest doses of the drug were likely to suffer from side effects. Many of those who were on these levels of the drug had to drop out of the study due to the side effects.

So the question for the FDA is whether or not the positive weight-loss results outweight the negative side effects.

Side effects include depression, anxiety, as well as sleep problems.

The drug, Qnexa, did meet its study goals though in human trials with weight loss ranging from 10% to 15%.